First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. (Q54499836)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. |
scientific article |
Statements
1 reference
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. (English)
1 reference
1 reference
1 reference
Saoirse Dolly
1 reference
Maria Martinez-Garcia
1 reference
Joan Albanell
1 reference
Rastilav Bahleda
1 reference
Federico Rojo
1 reference
Emilie Routier
1 reference
Ernesto Guarin
1 reference
Zhi-Xin Xu
1 reference
Ruediger Rueger
1 reference
Jean J L Tessier
1 reference
Eliezer Shochat
1 reference
Steve Blotner
1 reference
Valerie Meresse Naegelen
1 reference
Jean-Charles Soria
1 reference
3 July 2012
1 reference
1 reference
18
1 reference
4806-4819
1 reference
17
1 reference
Identifiers
1 reference